Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?
Puoti
Massimo
M
Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. m.puoti@iol.it
Babudieri
Sergio
S
Rezza
Giovanni
G
Viale
Pierluigi
P
Antonini
Maria Giulia
MG
Maida
Ivana
I
Rossi
Stefania
S
Zanini
Barbara
B
Putzolu
Valeria
V
Fenu
Luisa
L
Baiguera
Chiara
C
Sassu
Salvatore
S
Carosi
Giampiero
G
Mura
Maria Stella
MS
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007239:Infections / Q000139:chemically induced*; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007558:Italy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D011994:Recombinant Proteins; D012141:Respiratory Tract Infections / Q000139:chemically induced; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a